Search

Your search keyword '"Diemberger I."' showing total 22 results
Start Over Author "Diemberger I." Language italian
22 results on '"Diemberger I."'

1. Clinical management of older, frail patients with atrial fibrillation. The proposal of a multidisciplinary working group

Author

Marchionni N, Fumagalli S, Bo M, Boccanelli A, Boriani G, Rubboli A, Violi F, Di Pasquale G, Diemberger I, and Marchionni N, Fumagalli S, Bo M, Boccanelli A, Boriani G, Rubboli A, Violi F, Di Pasquale G, Diemberger I

Subjects
Disability, Elderly, Frailty, Frail Elderly, Atrial Fibrillation, Oral anticoagulant therapy, Anticoagulant, Geriatric Assessment, Direct oral anticoagulant, Aged, Human
Abstract

Atrial fibrillation (AF) is the most common arrhythmia in elderly people. Older patients with AF have several comorbidities and should be treated with complex therapeutic schemes. Arrhythmia complications are also common at an advanced age. Accordingly, AF can be considered a marker of frailty. Few indications can be found concerning the management of frail older subjects in current guidelines. The Frailty in Atrial Fibrillation Survey Study (FAST) was designed to overcome the gap of knowledge about this extremely vulnerable subset of patients. A multidisciplinary team composed by cardiologists, geriatricians and internists participated in the project. In a first phase, a survey was conducted aiming at clarifying specialty-related differences in definition and oral anticoagulant therapy (OAT) management of frail individuals. In the second phase, specific chapters were prepared about AF and frailty epidemiology, the network for the management of the arrhythmia, the diagnostic strategies for AF (including a minimum data set of tools derived from the geriatric multidimensional assessment), OAT and the choice between a rate or a rhythm control strategy. For each chapter, up-to-date evidence and current guideline recommendations were presented and discussed among the 47 Italian centers participating in the project. In the last phase of FAST, the results of the survey and the final draft of the chapters were merged into the present document. A lack of homogeneity in frailty definition existed. The integration among cardiologists, geriatricians and internists can represent the most effective tool to get through these differences improving the management of frail older patients.

Published
2021

2. The subcutaneous implantable cardioverter-defibrillator in clinical practice

Author

Migliore F., Mattesi G., Zorzi A., Viani S., Bongiorni M. G., Francia P., Curcio A., Diemberger I., Bertaglia E., Migliore F., Mattesi G., Zorzi A., Viani S., Bongiorni M.G., Francia P., Curcio A., Diemberger I., and Bertaglia E.

Subjects
Subcutaneous implantable cardioverter-defibrillator, Sudden cardiac death, Death, Sudden, Cardiac, Patient Selection, Electric Countershock, Humans, Arrhythmias, Cardiac, Defibrillators, Implantable
Abstract

Overcoming lead-related complications, the subcutaneous implantable cardioverter-defibrillator (S-ICD) represents the greatest advancement in the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Due to the absence of leads within the body, the S-ICD requires an innovative approach for sensing of subcutaneous signals and defibrillation. The aim of this review is to analyze the current evidence regarding patient selection, technical aspects such as the implant technique, programming and follow-up, as well as complications and troubleshooting of this innovative technology.

Published
2019

3. Controllo ambulatoriale del portatore di defibrillatore

Author

Biffi, M, Valzania, C, Bertini, M, Ziacchi, M, Saporito, D, Artale, P, Diemberger, I, Martignani, C, Boriani, Giuseppe, Frabetti, L, Branzi, A., M.SANTINI R.RICCI, Biffi M, Valzania C, Bertini M, Ziacchi M, Saporito D, Artale P, Diemberger I, Martignani C, Boriani G, Frabetti L, and Branzi A.

Published
2006

4. L'ottimizzazione degli intervalli AV e VV nei pazienti con device biventricolare: revisione della letteratura e contributo sperimentale

Author

Ziacchi, M., Bertini, M., Biffi, M., Martignani, C., Diemberger, I., Cervi, E., Valzania, C., Mazzotti, A., Gardini, B., Massaro, G., Moschini, C., Mantovani, V., Marziali, A., Boriani, Giuseppe, M Ziacchi, M Bertini, M Biffi, C Martignani, I Diemberger, E Cervi, C Valzania, A Mazzotti, B Gardini, G Massaro, C Moschini, V Mantovani, A Marziali, and G Boriani

Subjects
HEART FAILURE, CARDIAC RESYNCHRONIZATION THERAPY
Abstract

La terapia di resincronizzazione è una valida opzione nel trattamento dello scompenso cardiaco. Esiste ancora però una percentuale elevata di pazienti che non risponde in termini di rimodellamento ventricolare inverso. Con lo scopo di ridurre il numero di non responder, migliorando la sincronia di contrazione atrio-ventricolare e inter/intraventricolare, negli ultimi anni ha preso piede l’ottimizzazione della programmazione degli intervalli atrio-ventricolare e interventricolare. Facendo una revisione della letteratura si può notare che i contributi sperimentali sull’ottimizzazione dei parametri AV e VV sono diversi, utilizzano svariate tecniche di ottimizzazione e i trial multicentrici condotti fino a oggi portano a conclusioni controverse soprattutto per quel che riguarda l’intervallo VV. Nella seconda parte del lavoro abbiamo confrontato tre metodiche ecocardiografiche per la valutazione dell’intervallo VV ottimale (VTI, Strain circonferenziale e velocità). In primis, abbiamo dimostrato che l’ottimizzazione dell’intervallo VV ha determinato un maggior beneficio dopo impianto di CRT, rispetto alla programmazione standard in termini di rimodellamento ventricolare inverso. Inoltre, c’è una buona correlazione tra le tre metodiche utilizzate per ottimizzare l’intervallo VV; metodiche che non solo valutano la funzione sistolica del ventricolo sinistro ma anche la dissincronia.

Published
2010

5. La longevità dei defibrillatori impiantabili: implicazioni cliniche ed economiche. Abstract 69° Congresso Nazionale Società Italiana di Cardiologia

Author

Biffi, M., Ziacchi, M., Bertini, M., Sangiorgi, D., Corsini, D., Saporito, D., Diemberger, I., Martignani, C., Valzania, C., Moschini, C., Cervi, E., Domenichini, G., Marziali, A., Branzi, A., Boriani, Giuseppe, 166. M.Biffi, M.Ziacchi, M.Bertini, D.Sangiorgi, D.Corsini, D.Saporito, I.Diemberger, C.Martignani, C.Valzania, C.Moschini, E.cervi, G.Domenichini, A.Marziali, A.Branzi, and G.Boriani.

Published
2008

7. I problemi aritmologici nello scompenso cardiaco

Author

Boriani, Giuseppe, Frabetti, L., Biffi, M., Martignani, C., Diemberger, I., Branzi, A., PL.MALINI E.PERUGINI C.RAPEZZI, G.Boriani, L.Frabetti, M.Biffi, C.Martignani, I.Diemberger, and A.Branzi

Published
2006

8. Lo scompenso cardiaco: ruolo della terapia elettrica di resincronizzazione

Author

Boriani, Giuseppe, Biffi, M., Martignani, C., Ziacchi, M., Artale, P., Saporito, D., Valzania, C., Diemberger, I., Grigioni, F., Rapezzi, C., Frabetti, L., Branzi, A., G.Boriani, M.Biffi, C.Martignani, M.Ziacchi, P.Artale, D.Saporito, C.Valzania, I.Diemberger, F.Grigioni, C.Rapezzi, L.Frabetti, and A.Branzi

Published
2005

10. ETNA-AF study: Italian baseline data and comparison with the European population in atrial fibrillation patients treated with edoxaban

Author

Letizia, Riva, Igor, Diemberger, Giuseppe, Di Pasquale, Emilio, Attena, Raffaele, Sangiuolo, Raffaele, De Caterina, Riva L., Diemberger I., Di Pasquale G., Attena E., Sangiuolo R., and De Caterina R.

Subjects
Aged, 80 and over, Male, Registry, Pyridines, Middle Aged, Atrial fibrillation, Europe, Thiazoles, Italy, Real-world, Thromboembolism, Humans, Female, Registries, Edoxaban, Aged, Factor Xa Inhibitors
Abstract

The introduction of direct oral anticoagulants (DOACs) has been the main therapeutic revolution in the last 20 years. Four molecules have been approved for the thromboembolic prophylaxis in patients with non-valvular atrial fibrillation (AF). After the publication of phase 3 clinical trials, many studies evaluating DOAC safety and efficacy in daily clinical practice have been published. Edoxaban is the latest DOAC available on the market, based on the results of the ENGAGE AF-TIMI 48 trial. The phase 4 ETNA-AF (Edoxaban Treatment in Routine Clinical Practice for Patients With Non-Valvular Atrial Fibrillation) observational study was designed with the aim to confirm the results of the pivotal clinical trial in routine care in unselected patients with AF. This registry involved several sites and enrolled a large population in Europe and in Italy (13 980 and 3512 patients, respectively). The broad spectrum of patients will allow to have an overview of the characteristics of the AF population and to make a comparison with previous national registries and between different European realities.

Published
2020

15. Effetti della terapia di resincronizzazione cardiaca sulla funzione diastolica: valutazione con angiocardioscintigrafia con radionucleotide

Author

BORIANI, GIUSEPPE, MARTIGNANI, CRISTIAN, ZIACCHI, MATTEO, SAPORITO, DAVIDE, DIEMBERGER, IGOR, VALZANIA, CINZIA, BRANZI, ANGELO, Fallani F, Biffi M, Greco C, Pontone G, Gavaruzzi G, Levorato M, NICOLOSI GL, Boriani G, Fallani F, Biffi M, Martignani C, Ziacchi M, Saporito D, Greco C, Pontone G, Gavaruzzi G, Diemberger I, Valzania C, Levorato M, and Branzi A.

Published
2005

18. Effetti emodinamici del pacing biventricolare a distanza di un anno dall'impianto

Author

BORIANI, GIUSEPPE, MARTIGNANI, CRISTIAN, SAPORITO, DAVIDE, ZIACCHI, MATTEO, DOMENICHINI, GIULIA, DIEMBERGER, IGOR, VALZANIA, CINZIA, BRANZI, ANGELO, Biffi M, Artale P, NICOLOSI GL, Boriani G, Martignani C, Biffi M, Saporito D, Ziacchi M, Domenichini G, Artale P, Diemberger I, Valzania C, and Branzi A.

Published
2004

20. Terapia elettrica di resincronizzazione nei pazienti con scompenso cardiaco: ottimizzazione eco-guidata della programmazione dell'intervallo VV

Author

VALZANIA, CINZIA, BORIANI, GIUSEPPE, MARTIGNANI, CRISTIAN, ZIACCHI, MATTEO, SAPORITO, DAVIDE, DIEMBERGER, IGOR, BRACCHETTI, GIOVANNI, RAPEZZI, CLAUDIO, BRANZI, ANGELO, Biffi M, Fallani F, NICOLOSI GL, Valzania C, Boriani G, Martignani C, Biffi M, Ziacchi M, Saporito D, Diemberger I, Bracchetti G, Fallani F, Rapezzi C, and Branzi A.

Published
2004

21. [ETNA-AF study: Italian baseline data and comparison with the European population in atrial fibrillation patients treated with edoxaban].

Author

Riva L, Diemberger I, Di Pasquale G, Attena E, Sangiuolo R, and De Caterina R

Subjects
Aged, Aged, 80 and over, Atrial Fibrillation complications, Europe, Female, Humans, Italy, Male, Middle Aged, Registries, Thromboembolism etiology, Atrial Fibrillation drug therapy, Factor Xa Inhibitors administration & dosage, Pyridines administration & dosage, Thiazoles administration & dosage, Thromboembolism prevention & control
Abstract

The introduction of direct oral anticoagulants (DOACs) has been the main therapeutic revolution in the last 20 years. Four molecules have been approved for the thromboembolic prophylaxis in patients with non-valvular atrial fibrillation (AF). After the publication of phase 3 clinical trials, many studies evaluating DOAC safety and efficacy in daily clinical practice have been published. Edoxaban is the latest DOAC available on the market, based on the results of the ENGAGE AF-TIMI 48 trial. The phase 4 ETNA-AF (Edoxaban Treatment in Routine Clinical Practice for Patients With Non-Valvular Atrial Fibrillation) observational study was designed with the aim to confirm the results of the pivotal clinical trial in routine care in unselected patients with AF. This registry involved several sites and enrolled a large population in Europe and in Italy (13 980 and 3512 patients, respectively). The broad spectrum of patients will allow to have an overview of the characteristics of the AF population and to make a comparison with previous national registries and between different European realities.

Published
2020
Full Text
View/download PDF

22. [The subcutaneous implantable cardioverter-defibrillator in clinical practice].

Author

Migliore F, Mattesi G, Zorzi A, Viani S, Bongiorni MG, Francia P, Curcio A, Diemberger I, and Bertaglia E

Subjects
Arrhythmias, Cardiac physiopathology, Electric Countershock methods, Humans, Patient Selection, Arrhythmias, Cardiac therapy, Death, Sudden, Cardiac prevention & control, Defibrillators, Implantable
Abstract

Overcoming lead-related complications, the subcutaneous implantable cardioverter-defibrillator (S-ICD) represents the greatest advancement in the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Due to the absence of leads within the body, the S-ICD requires an innovative approach for sensing of subcutaneous signals and defibrillation. The aim of this review is to analyze the current evidence regarding patient selection, technical aspects such as the implant technique, programming and follow-up, as well as complications and troubleshooting of this innovative technology.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results